CERTIFICATE

IMPACT FACTOR 2021

Subject Area

  • Life Sciences / Biology
  • Architecture / Building Management
  • Asian Studies
  • Business & Management
  • Chemistry
  • Computer Science
  • Economics & Finance
  • Engineering / Acoustics
  • Environmental Science
  • Agricultural Sciences
  • Pharmaceutical Sciences
  • General Sciences
  • Materials Science
  • Mathematics
  • Medicine
  • Nanotechnology & Nanoscience
  • Nonlinear Science
  • Chaos & Dynamical Systems
  • Physics
  • Social Sciences & Humanities

Why Us? >>

  • Open Access
  • Peer Reviewed
  • Rapid Publication
  • Life time hosting
  • Free promotion service
  • Free indexing service
  • More citations
  • Search engine friendly

Disease-Free Survival In Patients Over 40 Years Of Age With Phneg Acute Lymphoblastic Leukemia Treated With An Intensive Protocol

Author: 
Alvarado Ibarra Martha, Ortiz Zepeda Maricela, Álvarez Vera José Luis, Mena Zepeda Verónica, Espitia Ríos María Eugenia, Jiménez Alvarado Rosa María and López Hernández Manuel
Subject Area: 
Health Sciences
Abstract: 

Introduction: Despitetheincreasingknowledgeabout acute lymphoblastic leukemia (ALL), the outcome for patients over 40 years of age is not good since they are generally too vulnerable to the toxicity caused by the chemotherapeutic protocols of the “pediatric type”. This group of patients usually tolerates less intensive protocols, but efficacy is diminished in terms of Survival Free of Leukemia. Objective: To determine the therapeutic results using a local, intensive protocol (LAL10), in patients with Phneg ALL that are older than 40 and are in a condition to receive intensive chemotherapy, treated in the hematology Service of the Centro MédicoNacional “20 de Noviembre” (National Medical Center) in Mexico City. Patients and Methods: From 2001 to 2015 an intensive chemotherapy program, with curative intent and designated as LAL10, was implemented in a High Specialization Center in Mexico City. The program was directed toward patients older than 40 with a de novo diagnosis of ALL, without an upper age limit. Patients were evaluated after the first dose of chemotherapy. Patients with previous use of anti-cancer agents or Ph+ were excluded. Those who abandoned treatment or went on to HPCT were eliminated. Results: Eighty-four patients who were in a condition to receive intensive chemotherapywere included. Medium age was 48 years with 26 patients older than 50 (31%). Female patients predominated. The frequency of complete remission was 74 (88%) and 10 patients were refractory. The most frequent event was relapse, constituting 47.6% of cases: 35 in bone marrow, 3 in skin and 2 in central nervous system. The probability for Leukemia-Free Survival to five years was 0.21 with a median of 14 months. The probability of Event-Free Survival was 0.17 with a median of 10 months. There were 32 deaths, 20 of which followed relapse or treatment failure and the other 12 happened between induction and up to the ninth month; the mode was 1 month. There were 7 deaths during induction. Causes of death were infection (24) and hemorrhage (8). The probability of OS at five years was 0.39 with a median of 25 months. Conclusion: In our experience, relapse was the most frequent event. Although this is not radically different from that observed in other studies on Phneg patients at comparable ages, these results are not considered to be satisfactory, especially when compared to results observed with the AYA group or in those younger than 15. Among the different protocols, chemotherapy usually includes the same drugs, although with different doses, and administration times and methods, but there is no indication of decisive beneficial changes.

PDF file: 

ONLINE PAYPAL PAYMENT

IJMCE RECOMMENDATION

Advantages of IJCR

  • Rapid Publishing
  • Professional publishing practices
  • Indexing in leading database
  • High level of citation
  • High Qualitiy reader base
  • High level author suport

Plagiarism Detection

IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.

 

EDITORIAL BOARD

Dr. Swamy KRM
India
Dr. Abdul Hannan A.M.S
Saudi Arabia.
Luai Farhan Zghair
Iraq
Hasan Ali Abed Al-Zu’bi
Jordanian
Fredrick OJIJA
Tanzanian
Firuza M. Tursunkhodjaeva
Uzbekistan
Faraz Ahmed Farooqi
Saudi Arabia
Eric Randy Reyes Politud
Philippines
Elsadig Gasoom FadelAlla Elbashir
Sudan
Eapen, Asha Sarah
United State
Dr.Arun Kumar A
India
Dr. Zafar Iqbal
Pakistan
Dr. SHAHERA S.PATEL
India
Dr. Ruchika Khanna
India
Dr. Recep TAS
Turkey
Dr. Rasha Ali Eldeeb
Egypt
Dr. Pralhad Kanhaiyalal Rahangdale
India
DR. PATRICK D. CERNA
Philippines
Dr. Nicolas Padilla- Raygoza
Mexico
Dr. Mustafa Y. G. Younis
Libiya
Dr. Muhammad shoaib Ahmedani
Saudi Arabia
DR. MUHAMMAD ISMAIL MOHMAND
United State
DR. MAHESH SHIVAJI CHAVAN
India
DR. M. ARUNA
India
Dr. Lim Gee Nee
Malaysia
Dr. Jatinder Pal Singh Chawla
India
DR. IRAM BOKHARI
Pakistan
Dr. FARHAT NAZ RAHMAN
Pakistan
Dr. Devendra kumar Gupta
India
Dr. ASHWANI KUMAR DUBEY
India
Dr. Ali Seidi
Iran
Dr. Achmad Choerudin
Indonesia
Dr Ashok Kumar Verma
India
Thi Mong Diep NGUYEN
France
Dr. Muhammad Akram
Pakistan
Dr. Imran Azad
Oman
Dr. Meenakshi Malik
India
Aseel Hadi Hamzah
Iraq
Anam Bhatti
Malaysia
Md. Amir Hossain
Bangladesh
Ahmet İPEKÇİ
Turkey
Mirzadi Gohari
Iran